Swedish Medtech innovation takes up the fight against medicines with serious side effects, and unnecessary surgical interventions
Globally, more than 400 million people suffer from reflux. A Swedish innovation – a neuromuscular training device – is leading the fight against both expensive surgical procedures and long term use of medicines that are connected to a range of serious side effects.
Millions of people take Proton Pump Inhibitor (PPI) medications every day for their reflux problems. For many years medical scientists have warned of the side effects of long-term use of these drugs. Side effects range from heart disease and stomach cancer to an increased risk of osteoporosis, intestinal infections and pneumonia.
In two newly published scientific studies, Taher Darreh-Shohi – assistant professor and researcher at the institute for neurobiology at Stockholm’s famous Karolinska Institute – has shown that long-term use of PPI medication can also significantly increase the risk of dementia and male infertility.
Reflux is caused by Hiatal hernia
IQoro is a neuromuscular training device that treats the underlying cause of reflux by stimulating the body’s natural internal communication systems. 90 seconds’ training per day has a proven effect according to many years’ scientific clinical research, financed mostly by the Swedish state. In studies using IQoro more than 98 % of users have improved significantly, and 73 % have become symptom free.
Treat the underlying cause instead of putting people at unnecessary risk
“Research clearly points out the serious risks of long-term use of PPI medication. In UK alone there are 13 million people on antacids. They deserve to be informed that they can address the underlying cause of their condition without unnecessary operations or drugs with side effects. Of course, PPIs can be necessary to use initially until the underlying problem is resolved, but long-term use should be avoided. We are daring to break the silence on this subject and are taking up the fight for people who are suffering unnecessarily”, says Linn Hägg, co-founder of MYoroface, the company behind IQoro.